Allarity Therapeutics Inc. (ALLR)
ALLR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/0001437749-26-010310-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALLR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001860657 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $320K |
| Net income | -$11.2M |
| Operating income | -$12.6M |
| Net margin | -3509.7% |
| Operating margin | -3939.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $14.7M |
| Total assets | $18.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 43.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $17.0M cash; operating cash flow -$3.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 15,997,108 (2026-11-12); 15,811,886 a year earlier; 4,558,623 three years earlier. 3y figure adjusted for splits (1-for-600 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 2; latest 1-for-30 on 2024-09-11 | Source 2024-09-11 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2026-01-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Wolf & Company, P.C., Boston, Massachusetts, United States | PCAOB Form AP 2026-04-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$3.4M | -$2.6M | $17.0M | $22.3M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $25K | -$2.8M | -$4.5M | $19.8M | $21.5M | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$3.4M | -$3.2M | $14.7M | $1.4M | $320K | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$2.8M | -$3.4M | $16.9M | $1.4M | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $0 | -$2.3M | -$5.5M | $17.8M | $1.4M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | -$2.7M | -$2.7M | $25.2M | $1.4M | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$7.5M | -$3.2M | $19.5M | $2.7M | $0 | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$11.6M | -$5.4M | $18.5M | $1.3M | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-10-30 |
| Latest annual report FORM 10-K | 10-K | 2026-03-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-13 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-02 |
| Latest proxy PROXY STATEMENT | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 404 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.1% |
| 1 month | +9.7% |
| 3 months | -29.9% |
| Year to date | -11.7% |
| 1 year | -19.8% |
| From 52-week high | -46.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MRKR | Marker Therapeutics Inc. | $0.8286 | -4.76% | $13.8M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
| NEUP | Neuphoria Therapeutics Inc. | $2.48 | -2.75% | $13.4M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| CMMB | Chemomab Therapeutics Ltd. American Depositary Share | $1.62 | +5.88% | $13.0M |
| KYNB | Kyntra Bio Inc. | $3.20 | -8.31% | $13.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier